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Abstract
Introduction: There are several HIV drug resistant interpretation algorithms 
which produce different resistance measures even if applied to the same 
resistance profile. This discrepancy leads to confusion in the mind of the 
physician when choosing the best ARV therapy.
Aim: The aim of this study is to combine the interpretation of three gold 
standard interpretation algorithms using multilayer perceptron neural 
networks in order to produce a single resistance measure.
Methods: The REGA, HIVdb and ANRS algorithms were applied to protease 
and reverse transcriptase genome sequences. This output together with the 
relevant IC50 based resistance measures were fed into three different 
multilayer perception neural networks.
Results: The three neural network models increased the average accuracy of 
the protease sequence from 61% to 76.3% and 58% to 63% for reverse 
transcriptase sequences.
Conclusion: Results show that combining the international gold standards 
using neural networks produces better ARV drug resistance prediction 
models.
Keywords: Machine learning, Artificial intelligence, Neural networks, HIV 
drug resistance 
1. INTRODUCTION
1.1 Background
The human immunodeficiency virus (HIV) is an enveloped virus that belongs 
to the family of retroviridae and to the genus lentivirus. This means that the 
viral infection is characterized by a long latent period, and thus accounts for 
the HIV's ability to infect and destroy the immune system of a human over a 
long period of time. There are two known strains of the HIV, i.e. HIV-1 and HIV-
2 (Wilson,2002). Functionally, the HIV-2 is not as pathogenic as the HIV-1, 
meaning that the rate of replication and infection of the HIV-2 is substantially 
slower than that of the HIV-1. The HIV-1 accounts for the vast majority of HIV 
infections in the world, and it is estimated that 95% of all infection are due to 
the HIV-1 (Quinn,1998). 
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There are currently almost 5.6 million infected with HIV in South Africa, which 
is approximately 11% of the South African population (AIDS Committee of 
Actuarial Society of South Africa, 2008).  It is also estimated that there are 
almost 500 000 patients who exhibit AIDS defining conditions in South Africa 
(Health Systems Trust, 2011). The prevalence of HIV in some countries as 
well as the prevalence in the nine provinces of South Africa is shown in Table 
One [Health Systems Trust, 2011; Central Intelligence Agency, 2011). The 
high prevalence of HIV in Africa, and the contrast between developing and 
developed countries is clearly seen. 
Table 1: Prevalence of HIV for each country as reported by the Central 
Intelligence Agency of the United States (Central Intelligence Agency, 2011), 
and for each province in South Africa as per Health Systems Trust (Health 
Systems Trust, 2011).
Country Prevalence% Country
 
Prevalence %
Swaziland 25.90
 
France
 
0.40
Botswana 24.80 Spain 0.40
Lesotho 23.60
 
Italy
 
0.30
Zimbabwe 14.30 India 0.30
Zambia 13.50
 
Netherlands
 
0.20
Namibia 13.10
 
United Kingdom 0.20
Mozambique 11.50
 
Australia
 
0.10
Malawi 11.00
 
Germany
 
0.10
Uganda 6.50
 
Greece
 
0.10
Kenya 6.30
 
New Zealand
 
0.10
Tanzania 5.60
 
Afghanistan 0.01
Nigeria 3.60 Svalbard 0.00
South Africa -
Kwazulu-
Natal
14.9 South Africa-
Eastern Cape
10.6
South Africa-
Mpumalanga
12.5 South Africa-
Limpopo
7.0
South Africa-
North West
12.4 South Africa-
Northern Cape
6.7
South Africa-
Free State
12.0 South Africa-
Western Cape
5.6
South Africa-
Gauteng
11.2
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There is currently no cure or publically available vaccine for HIV infection. 
However HIV may be managed by highly active antiretroviral therapy. Highly 
active antiretroviral therapy comprises of a regimen of three antiretroviral 
(ARV) drugs from at least two of the possible five drug classes, namely, 
protease inhibitors, reverse transcriptase inhibitors, integrase inhibitors, 
fusion inhibitors, and entry inhibitors. Each ARV class works by inhibiting 
different stages in the replication cycle of HIV from the attachment to CD  cells 
4
to the cleavage and subsequent formation of viron. 
Several factors contribute to the failure of highly active antiretroviral therapy. 
These include poor treatment, stage of the disease, drug potency, patient 
adherence, achievable drug levels, drug resistance (Richman et al., 2000), 
and toxic effects of the drugs. Of these factors, drug resistance is arguably the 
most critical. Drug resistance is defined as the inability of antiretroviral drugs 
to reduce the HIV viral load below detectable levels i.e. significantly inhibit HIV 
replication. It was reported in 2009, that 37% of patients that required ARV 
treatment actually received ARV drugs in South Africa (Adam et al., 2009).   It 
is inevitable that drug resistance will become a concern in the treatment of 
HIV/AIDS infected patients due to the high replication rates of the virus, 
selective pressure caused by the ARV drugs and initial infection by resistant 
strains of HIV.
Phenotypic assays are a direct in-vitro method of measuring ARV drug 
resistance. A phenotypic test comprises of cultivating the HIV that has infected 
a patient in a sterile and controlled laboratory environment. The concentration 
of a specific ARV to reduce the replication rate of the HIV by 50 % in the culture 
is compared to the concentration of ARV required to reduce the replication rate 
of the wild-type HIV by 50% in a similar environment. The ratio of these two 
concentrations is called the IC  score. The IC  score is compared to 
50 50
predetermined literature based susceptible cutoffs to determine if a particular 
patient is resistant to ARVs as shown in Equation One.  
Phenotypic tests are relatively expensive, time consuming, susceptible to 
error and each test detects resistance to a single drug and thus many tests are 
required to determine multiple drug resistances (Bartlett et al., 2004). 
Electronic computerized algorithms (Jaideep et al., 2003) may also be used to 
determine ARV drug resistance, and have many advantages over phenotype 
testing. Computer based genotype interpretation algorithms usually 
determine mutations in the patient's pol gene region, and uses this information 
to determine which ARV drugs the patients are resistant to. These computer 
based tests are faster and cheaper than phenotypic tests.
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Computer based gold standard interpretation algorithms are usually based on 
an experts' understanding of the domain, available datasets that are used for 
machine learning and understanding of published literature. This has led to 
the creation of many different interpretation algorithms, which produce 
different resistance measures even if applied to the same resistance profile. 
During treatment of complex ARV resistance these different international gold 
standards are a source of discrepancy and create confusion in the mind of the 
physician in terms of choosing the best ARV therapy.
Thus the aim of this study is to combine the interpretation of three gold 
standard interpretation algorithms using multilayer perceptron neural 
networks in order to produce a single resistance measure and to determine if 
the combined algorithm better predicts HIV drug resistance.
The next section describes the three international gold standards and how 
multilayer perceptron neural networks work.
1.2. Interpretation algorithms
One type of interpretation algorithm is based on domain knowledge. These 
interpretation algorithms are logic or decision tree based expert systems that 
are made up of rules describing interactions between certain mutations and/or 
combination of mutations with resistance. This means that all computational 
decisions concerning resistance are based on known mutation-resistance 
rules found in published scientific literature.  
REGA, Agence Nationale de Recherches sur le SIDA (ANRS) and HIV-db are 
widely used as the gold standards in ARV drug resistance interpretation 
algorithms. REGA was developed by the laboratory for clinical and 
evolutionary virology, Rega Institute for Medical Research, Katholieke 
Universiteit Leuven. The HIV-db program was developed by the Division for 
Infectious Diseases, Stanford University Medical Center, Stanford University. 
The French National Agency for AIDS Research AC11 Resistance group 
developed the ANRS algorithm.
These interpretation algorithms were developed using different datasets, 
subtypes, and are analyzed on drug-naive and -experienced patients. These 
differences have led to the creation of different interpretation algorithms. Initial 
studies suggested that the interpretation algorithms produce different 
resistance measures even if applied to the same resistance profile. Recent 
studies with updated interpretation rules still suggest some discordance 
between interpretation algorithms [Jaideep et al, 2003; de Luca, 2003; de 
Luca, 2004; Wang et al., 2011; Verge et al, 2006; Snoek et al., 2006; 
Vercauteren, 2006; Poonpiriya, 2008; Yebra, 2010). 
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1.3. Multilayer Peceptron Neural Network
All neural networks contain an electronic representation of the human neuron. 
These networks interconnect these neurons in various manners in order to 
perform learning. Similar to the dentrites attached to the axon of the human 
neuron, the electronic neuron has channels which transport input (α) into the 
core of the neuron. The electronic neuron has weights (ϖ) and an external 
stimuli called the bias (β). The electronic neurons may or may not ﬁre 
depending on the value of the product (θ) and summation of the inputs, 
weights and bias, and on the type of activation function (Ψ) that is used. 
Mathematically a neuron can be described as shown in Equations Two and 
Three, and graphically as shown in Figure One. 
Figure 1: Shows the interaction between inputs, bias and weights.
The simple perceptron can only perform linear separation. In most pattern 
classification problems non-linear separation is required and this is achieved 
by layering perceptrons into a multilayer perceptron (MLP). These layers are 
divided into input, hidden and output layers as indicated by Figure Two. Each 
neural network neuron receives input from the neural network neurons in the 
previous layer and is then multiplied by weights. The weighted inputs are 
summed, and passed through an activation function which scales the output 
to either being 0 or 1. This scaled value is then broadcast to each of the 
neurons in the next layer. To use the network to solve a problem, the input 
space values are applied to the inputs of the first layer, and the signals are 
allowed to propagate through the network, eventually predicting the output 
values. These perceptrons are independent of each other, and are thus 
trained as such. 
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Figure 2: Shows the structure of an MLP with input, hidden and output layers.
2. METHODOLOGY
2.1 Data Processing
Genotype-Phenotype datasets that consisted of 2,928 protease genes and 
1,981 reverse transcriptase gene sequences were obtained from the Stanford 
HIV drug resistance database (http://hivdb.stanford.edu/). This database 
contains publically available de-identified HIV drug resistance data. The 
amino acid for each protease and reverse transcriptase sequence in the 
dataset was then processed into its respective three base nucleotide 
sequence. The nucleotide list was then fed into to the online HIValg V6.0.11 
program hosted by Stanford University. This web application takes as input 
the nucleotide list, converts this to an amino acid list, determines mutations 
that occur in the genome, and calculates a resistance measure, namely, 
resistant, susceptible and intermediate, for a sequence by applying the 
REGA, HIVdb and ANRS algorithms individually to it. These resistance 
measures then form the input to the machine learning algorithm. 
The predicted output resistance measure for each sequence was linked with 
its original amino acid sequence and its associated phenotype IC  score.  
50
With respect to this study, the IC scores were treated as a true measurement 
50 
of drug resistance. Based on the ranges of the IC  score, an actually 
50
resistance measurement was determined and these acted as the output of the 
machine learning algorithm during the learning step. This process is shown in 
Figure Three.
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Figure 3: Shows the steps involved in the methodology employed to obtain a 
single ARV drug resistance interpretation.
2.3. Neural Network
Three multilayer perception neural networks called MLPNN1, MLPNN2, and 
MLPNN3 respect ive ly  were created us ing NeuroSolut ions 
(http://www.neurosolutions.com/). MLPNN1 consisted of one hidden layer 
with 50 processing elements. MLPNN2 consisted of two hidden layers with 10 
and 5 neurons respectively. MLPNN3 comprised of three hidden layers with 
10, 15 and 5 neurons per layer respectively. All three neural networks used a 
momentum learning rule, a step size of 0.1, and a momentum of 0.7. The 
multilayer perceptron neural networks are shown in Figures Five-Seven.
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Figure 5: Shows the structure of the MLPNN1, with one hidden layer and 50 
neurons.
Figure 6: Shows the structure of the MLPNN2, with two hidden layers 
consisting of 10 and 5 neurons.
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Figure 7: Shows the structure of the MLPNN3, with three hidden layers 
consisting of 10, 15 and 5 neurons.
2.4 Statistical Analysis
Standard deviation, z-score and p-score were calculated in order to perform a 
proportion Z-test. The standard deviation was calculated as shown in 
Equation Four and the Z-score as calculated from Equation Five. P-scores 
were determined by solving Equation Six. These were calculated to determine 
if the accuracies obtained were statistically different from chance. Similarly the 
proportional Z-test was used to determine if the difference between the 
algorithms were statistically significant. 
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3. RESULTS
In order to determine which of the three neural networks best classifies the 
resistance profiles, the accuracies, average sensitivities, specificities, positive 
predictive value and negative predictive value for the protease (Table Two) 
and reverse transcriptase sequences (Table Three) were calculated. 
Accuracy is defined as the percentage of resistance profiles that have 
resistance measures as identified by the IC  score. 
50
Sensitivity for the resistance measure was determined by calculating the 
number of predicted patient's resistance profiles that was correctly predicted 
as resistant compared to all patient resistance profiles that should have been 
predicted as resistant. These were calculated for the intermediate and the 
susceptible measures as well. The overall sensitivity was found by averaging 
the three sensitivities for the resistance, intermediate and susceptibility 
measures. 
Specificity for the resistance measure was determined by calculating the 
number of predicted patient's resistance profiles that was correctly predicted 
as not resistant compared to all patient resistance profiles that should have 
been predicted as not begin resistant.  The overall specificity was found by 
averaging the three specificities for the resistance, intermediate and 
susceptibility measures. 
Positive predictive value is defined as the average proportion of patients with 
resistance profiles correctly diagnosed as resistant, susceptible and 
intermediate. Negative predictive value was similarly calculated.
 
Table 2: shows accuracies, sensitivities, specificities, positive predictive value 
and negative predictive value for the protease sequences using the ANRS, 
HIV-db and REGA algorithms.  
Measure ANRS Hiv-Db REGA MLPNN1 MLPNN2 MLPNN3
Accuracy/% 62 62 61
 
75
 
77
 
77
 Sensitivity/%
 
92
 
91
 
92
 
Specificity/% 78 78 81
PPV/% 73 75 78
NPV/% 93 93 93
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Table 3: shows accuracies, sensitivities, specificities, positive predictive value 
and negative predictive value for the reverse transcriptase sequences using 
the ANRS, HIV-db and REGA algorithms and the multilayer perceptron 
models.  
Measure ANRS Hiv-
db
REGA
 
MLPNN1
 
MLPNN2
 
MLPNN3
 
Accuracy/% 57 58 59 63 63 63
Sensitivity/
%
 
66
 
65
 
67
 
Specificity/
%
75 76 76
PPV/% 81 82 82
NPV/% 58 56 63
Table 4: shows the Z-scores when comparing accuracies, sensitivities, 
specificities, positive predictive value and negative predictive value for the 
protease and reverse transcriptase sequences against chance using the 
ANRS, HIV-db and REGA algorithms. (* indicates p <0.001)
Measure Protease Sequences
 
Reverse Transcriptase Sequences
 
MLPNN1 MLPNN2
 
MLPNN3 MLPNN1 MLPNN2 MLPNN3
 Accuracy 27.1* 29.2*
 
29.2*
 
11.6*
 
11.6*
 
11.6*
 
Sensitivity 45.5* 44.4*
 
45.5*
 
14.2*
 
13.4*
 
15.1*
 
Specificity 30.3* 30.3* 33.5* 22.3* 23.1* 23.1*
PPV 27.1* 24.9* 30.3* 27.6* 28.5* 28.5*
NPV 46.5* 46.5* 46.5* 7.1* 5.3* 11.6*
In order to determine which of the three neural network algorithms performed 
the best in terms of most effectively modeling the domain, each of the 
algorithms were compared against each other using the proportional Z-test as 
per Equations 4 to 6. These results are reflected in Table 5. Furthermore to 
determine if the difference between the best neural network and the three 
international gold standards are significant, the proportional z test was 
performed. These results are shown in Table 6.
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Table 5: shows the Z-scores when comparing accuracies, sensitivities, 
specificities, positive predictive value and negative predictive value for the 
protease and reverse transcriptase sequences against chance. (* indicates p 
<0.001)
Protease Sequence
 
Reverse transcriptase Sequence
 
 
MLPNN1 MLPNN2 MLPNN1
 
MLPNN2
 
MLPNN2 MLPNN3 MLPNN3 MLPNN2
 
MLPNN3 MLPNN3
 
Accuracy 2.1*
2.1*
 
0
 
(p=1)
 
0
 
(p=1)
 
0
 
(p=1)
 
0
 
(p=1)
 
Sensitivity -1.7
(p=0.045)
0
(p=1)
 
-1.6
 
(p=0.54)
 
-0.92
 
(p=0.17)
 
0.93
 
(p=0.17)
-1.9
 
(p=0.028)
 
Specificity 0
(p=1) 3.2* -3.4*
1.1
(p=0.13)
1.0
(p=0.15)
0
(p=1)
PPV
-2.3* 3.0* 5.3*
1.1
(p=0.13)
1.1
(p=0.13)
0
(p=1)
NPV 0
(p=1)
0
(p=1)
0
(p=1)
-1.8
(p=0.035) 4.4* -6.4*
Table 6: shows the Z-scores when comparing accuracies of ANRS, HIV-db 
and REGA against MLPNN3 the protease and reverse transcriptase 
sequences. (* indicates p <0.001)
Gold 
Standard Protease
Reverse 
Transcriptase
ANRS 13.6* 5.3*
HIV-db 13.6* 4.4*
REGA 14.4* 3.6*
4. ANALYSIS
For the protease sequence, the three neural network models produced an 
average accuracy of 76.3 ± 1.1% (95% CI), sensitivity of 91.6 ± 0.5% (95% CI), 
specificity of 79 ±  1.7% (95% CI), PPV of 75.3 ±  2.5 %( 95% CI), and NPV of 
93 ± 0% (95% CI). For the reverse transcriptase sequence, the three neural 
network models produced an average accuracy of 63 ± 0% (95% CI), 
sensitivity of 66 ± 1% (95% CI), specificity of 75.6 ± 0.6% ( 95% CI), PPV of 
81.6 ± 0.6% (95% CI), and NPV of 59 ±  3.6% (95% CI). Table Four shows that 
the MLPNN1, MLPNN2, and MLPNN3 predicted ARV drug resistance 
measures more effectively than chance as shown by the p<0.001 for all of the 
accuracy, sensitivity, specificity, PPV and NPV's for both the protease and 
reverse transcriptase sequences in Table Four. This indicates that the three 
machine learning algorithms have created a mathematical model that 
emulates the domain knowledge and that the predication is not based on 
random chance. 
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Table Five shows that there is statistical difference between the MLPNN1 and 
MLPNN2 algorithms in terms of accuracy and positive predictive value with 
the protease sequences, and from Table 4 it may be deduced that MLPNN2 
better predicts ARV drug resistance measures. Similarly, there MLPNN3 has a 
statistically significantly higher accuracy, sensitivity and PPV than MLPNN1. 
MLPNN3 also has a higher specificity and PPV than MLPNN2. Thus one may 
deduce that MLPNN3 better predicts ARV drug resistance measures using 
protease sequences.
Table 5 also shows that there is statistical difference between the MLPNN1 
and MLPNN3 algorithms in terms of negative predictive value with the reverse 
transcriptase sequences, and from Table 4 it may be deduced that MLPNN3 
better predicts ARV drug resistance measures.  Similarly, the MLPNN3 has a 
statistically significantly higher NPV than MLPNN2. Thus one may deduce 
that MLPNN3 better predicts ARV drug resistance measures using reverse 
transcriptase sequences.
It is evident from the p<0.001 for all comparisons shown in Table 6, that 
combining the international gold standards using neural networks produces a 
statistically significantly better ARV drug resistance prediction model. 
5. CONCLUSIONS
Results from this study show that combining the international gold standards 
using neural networks produces a statistically significantly better ARV drug 
resistance prediction model. Further research should be directed to improving 
the effectiveness of the combination by using other machine learning 
techniques and expanding the data set in terms of more predictors and tuples 
of data.
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